Careers at Syantra
At Syantra, we’re on a mission to change the way cancer is treated and detected, starting with breast cancer. It’s an ambitious goal, but thanks to the efforts of our remarkable, passionate team, we’re making progress. We’re growing quickly and looking for exceptional performers to join our team as we go the distance.
Join our team
Help shape the future of precision medicine in a dynamic, supportive, science-driven work environment. You’ll be working with a world-class team of scientists, technicians and business leaders in an innovative and collaborative Calgary office/lab space.
Working and living in Calgary
Calgary has been named the world’s fifth most livable city by The Economist magazine for seven years in a row, earning top marks for stability, healthcare and education. Here are a few more aspects of our city that make it a truly great place to live:
- Calgary is a vibrant city with a young, diverse population and thriving arts and cultural scene.
- Calgary is just a 45 minute drive from the spectacular Canadian Rockies and all the recreation opportunities offered there.
- Calgary’s cost of living is among the lowest for major Canadian cities and the median income in our province is more than 18 percent higher than the national average.
- Calgarians enjoy more days of sunshine than any other major Canadian city, which is great, since our city has over 100 parks and green spaces that are perfect for enjoying those rays.
Check back soon for our latest career opportunities
Our latest news and stories
Syantra announces additions to their Intellectual property (IP) portfolio as well as a strategic partnership with Limmi, a US-based technology company using AI-driven insights to power next generation disease detection and management techniques. These achievements mark significant milestones for Syantra and represent major advancements in understanding human disease.
Syantra announced today that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat. Securing CE marking allows the company to market the blood test in the European Union and other countries that recognize the designation.
Syantra Inc. announced today the promotion of Carol Roesler to Vice President, effective January 2023.
Carol will maintain her current responsibilities in her new role, in addition to supporting Canadian business development for the Syantra DX™ Breast Cancer test.
Syantra will present findings from the IDBC Study at the 13th European Breast Cancer Conference, held in Barcelona, Spain from 16 -18 November 2022.
Syantra appoints Dr. Massimo Cristofanilli, a world-renowned leader in the field of breast cancer, to its Scientific Advisory Board (SAB) effective Sept 1, 2022. Dr. Cristofanilli is a Professor of Medicine, Chief of Breast Medical Oncology and Associate Director of Precision Medicine at Weill-Cornell Medicine.
With the arrival of Breast Cancer Awareness month, Calgary precision biotechnology company, Syantra Inc., is announcing a program to help younger women expand their knowledge of breast cancer and early detection. As part of this program, Syantra is launching the 18% Initiative to draw awareness to the percentage of breast cancer diagnoses in women under 50.
Last fall, organizers at the San Antonio Breast Cancer Symposium (SABCS) provided an opportunity for Syantra to present interim results from the company’s ongoing international clinical study, Identify Breast Cancer (IDBC), to show the performance of the Syantra DX | Breast Cancer screening test. Syantra's Dr. Kenneth Fuh speaks to why this was a significant juncture for the team.
Alberta-based precision biotechnology company, Syantra Inc. has spent nearly a decade developing a blood test for the early detection of breast cancer. In winter 2020, the Syantra team took one of those big steps towards their goal. They began working with the College of Physicians and Surgeons of Alberta (CPSA) to gain lab accreditation to enable commercial operations.
In March 2020, the whole world paused. Normal life was suspended in time as we reckoned with the reality of a global pandemic. But cancer doesn’t pause for a pandemic.
In October 2017, Syantra received ASBIRI program funding for the early detection of cancer in partnership with Alberta Innovates, the Alberta Cancer Foundation (ACF) and DynaLIFE Medical Laboratories.
